444OPHASE IB TRIAL TRIAL OF RG7116, A GLYCOENGINEERED MONOCLONAL ANTIBODY TARGETING HER3, IN COMBINATION WITH CETUXIMAB OR ERLOTINIB IN PATIENTS WITH ADVANCED/METASTATIC TUMORS OF EPITHELIAL CELL ORIGIN EXPRESSING HER3 PROTEIN.
暂无分享，去创建一个
S. Sleijfer | J. Schellens | C. Adessi | M. Martínez-García | M. D. de Jonge | B. Bossenmaier | D. Meulendijks | U. Lassen | A. C. Ruipérez | Á. Taus | F. Michielin | I. James | T. Fleitas | W. Jacob | M. Weisser | M. Mau-Soerensen | G. Meneses-Lorente | A. Keelara | M. Lolkemar